---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-076278"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:20:27.445042+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences reports Q4 2022 net loss $43.7M; cash runway into 2025 on $170M GSK upfront

## Summary
- Q4 2022 net loss $43.7M vs $34.8M in Q4 2021; full-year 2022 net loss $161.8M vs $122.2M in 2021.
- Cash and equivalents $88.5M at Dec 31, 2022; after period-end, received $170M upfront from GSK collaboration.
- GSK collaboration includes up to $3.3B in potential milestones; Wave licensed WVE-006 for AATD to GSK.
- WVE-006 on track for CTA submission in 2H 2023; Part B of WVE-N531 DMD study to begin in 2023 with dystrophin data in 2024.
- Single-dose data from WVE-003 (HD) and WVE-004 (ALS/FTD) expected in 1H 2023; Takeda option for 50:50 co-development.

## SEC filing metadata
- accession: 0001193125-23-076278
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312523076278/0001193125-23-076278-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312523076278/d451722d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-076278
- JSON: https://secwatch.observer/filing/0001193125-23-076278.json
- Plain text: https://secwatch.observer/filing/0001193125-23-076278.txt

## Key facts
- Earnings Releases
  Wave Life Sciences Ltd. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 22, 2023, Wave Life Sciences Ltd. announced its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523076278/0001193125-23-076278-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.